New obesity drug from Lilly delivers major weight loss
The Hill
—
An investigational obesity drug from Eli Lilly cleared important endpoints in a late-stage trial, the company said Thursday, by helping patients lose up to 30 percent of their body weight.
Lilly said that a once-weekly injection of retatrutide met the primary endpoint in a phase 3 clinical trial, as well as key secondary endpoints for obesity, delivering clinically meaningful weight loss.
The highest dose of retatrutide helped patients lose 28.3…
Lilly weight loss drug results
- A Next-Generation Drug Causes Dramatic Weight Loss, Eli Lilly Says Time —
- New Eli Lilly weight loss drug has dramatic effects in clinical trial Washington Examiner —
- Eli Lilly says next-gen obesity drug helps patients lose 28% of body weight - Reuters Reuters —
- New weight-loss shot appears to outperform other obesity drugs on market The Guardian —
- Eli Lilly’s next-gen obesity drug beats Ozempic and Mounjaro, helps patients lose over 30% body weight in trial The Indian Express —